AbbVie Long Term Debt

The latest long-term debt for 4AB.DE is $62B as of June 2026. That compares with $63B in the prior-year period — down 0.8% year over year. Investors often review this figure alongside AbbVie's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4AB.DE's long-term debt moved from $63B to $62B — a 0.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AbbVie's operating scale or balance-sheet position.

A long-term debt figure of $62B for 4AB.DE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4AB.DE's long-term debt ($62B), review year-over-year change from $63B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack AbbVie's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.